Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Liabilities from Discontinued Operations: 2023-2024

Historic Liabilities from Discontinued Operations for Anika Therapeutics (ANIK) over the last 2 years, with Dec 2024 value amounting to $4.1 million.

  • Anika Therapeutics' Liabilities from Discontinued Operations fell 61.83% to $4.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.1 million, marking a year-over-year decrease of 61.83%. This contributed to the annual value of $4.1 million for FY2024, which is 61.83% down from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Liabilities from Discontinued Operations is $4.1 million, which was down 61.83% from $10.8 million recorded in FY2023.
  • Anika Therapeutics' 5-year Liabilities from Discontinued Operations high stood at $10.8 million for FY2023, and its period low was $4.1 million during FY2024.
  • Over the past 2 years, Anika Therapeutics' median Liabilities from Discontinued Operations value was $7.5 million (recorded in 2023), while the average stood at $7.5 million.
  • Data for Anika Therapeutics' Liabilities from Discontinued Operations shows a maximum YoY plummeted of 61.83% (in 2024) over the last 5 years.
  • Over the past 2 years, Anika Therapeutics' Liabilities from Discontinued Operations (Yearly) stood at $10.8 million in 2023, then crashed by 61.83% to $4.1 million in 2024.